for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Flexion Therapeutics Inc

FLXN.OQ

Latest Trade

14.24USD

Change

-0.18(-1.25%)

Volume

258,459

Today's Range

13.80

 - 

14.80

52 Week Range

8.78

 - 

19.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Flexion Therapeutics Announces Extended FDA Review Of Supplemental New Drug Application For Zilretta

Oct 14 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES EXTENDED FDA REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION FOR ZILRETTA®.FLEXION THERAPEUTICS INC - FDA INFORMED CO IT NEEDS ADDITIONAL TIME TO COMPLETE REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR ZILRETTA.FLEXION THERAPEUTICS INC - FDA DID NOT PROVIDE A NEW ACTION DATE FOR ZILRETTA.FLEXION THERAPEUTICS INC - FDA INFORMED CO THAT REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION FOR ZILRETTA IS EXPECTED TO BE COMPLETED IN COMING WEEKS.

Flexion Therapeutics Posts Qtrly Loss Per Share Of $0.96

Aug 6 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS SECOND-QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 SALES $17 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.7 MILLION.QTRLY LOSS PER SHARE $0.96.Q2 EARNINGS PER SHARE VIEW $-1.05 -- REFINITIV IBES DATA.

Flexion Therapeutics Announces Publication Of Independent Data Review Of Zilretta In The Journal Drugs

April 2 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES PUBLICATION OF INDEPENDENT DATA REVIEW OF ZILRETTA® (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN THE JOURNAL DRUGS.FLEXION THERAPEUTICS INC - EVALUATION CONCLUDED THAT ZILRETTA PROVIDED EFFECTIVE PAIN RELIEF, WAS GENERALLY WELL-TOLERATED.FLEXION THERAPEUTICS INC - COMPREHENSIVE REVIEW INCLUDED DATA FROM SIX CLINICAL STUDIES INVOLVING MORE THAN 1,300 PATIENTS.FLEXION THERAPEUTICS INC - EVIDENCE-BASED EVALUATION CONCLUDED THAT ZILRETTA PROVIDED EFFECTIVE PAIN RELIEF.FLEXION THERAPEUTICS INC - EVIDENCE-BASED EVALUATION CONCLUDED THAT ZILRETTA EXPANDS TREATMENT OPTIONS FOR OSTEOARTHRITIS (OA) KNEE PAIN.

Flexion Therapeutics Announces Preliminary, Unaudited Q4 2018 Results

Jan 3 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH-QUARTER AND FULL-YEAR 2018 REVENUE AND INITIAL REVENUE GUIDANCE FOR 2019.SEES FY 2018 REVENUE $22.5 MILLION.SEES Q4 2018 REVENUE $9.5 MILLION.FULL-YEAR 2018 REVENUE ESTIMATED TO BE APPROXIMATELY $22.5 MILLION.FLEXION PROVIDING INITIAL 2019 PRODUCT REVENUE GUIDANCE OF $65 TO $80 MILLION.ANTICIPATES 2019 ZILRETTA PRODUCT REVENUE TO BE IN RANGE OF $65 TO $80 MILLION.Q4 REVENUE VIEW $10.2 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $23.1 MILLION -- REFINITIV IBES DATA.

Flexion Therapeutics Enrolls First Patient In Phase 3 Trial Of Zilretta In OA Of The Hip

Jan 2 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 3 TRIAL OF ZILRETTA® (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN OA OF THE HIP AND REPORTS RESULTS FROM SHIP STUDY.FLEXION THERAPEUTICS INC - PHASE 3 HIP OA REGISTRATION TRIAL EXPECTED TO COMPLETE IN 2020.FLEXION THERAPEUTICS - ADDITIONAL PHASE 2 STUDIES OF SHOULDER OA AND ADHESIVE CAPSULITIS (FROZEN SHOULDER) PLANNED FOR H2 2019.FLEXION-POSITIVE RESULTS FROM PHASE 2 PHARMACOKINETICS STUDY OF ZILRETTA IN OA OF SHOULDER, HIP SHOWED PROFILES CONSISTENT WITH OLDER STUDIES IN KNEE.FLEXION THERAPEUTICS INC - PHASE 2 RESULTS DEMONSTRATED THAT ZILRETTA WAS GENERALLY SAFE AND WELL TOLERATED.

Flexion Therapeutics Reports Q3 Sales of $7.0 Million

Nov 7 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS THIRD-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 SALES $7.0 MILLION VERSUS I/B/E/S VIEW $6.7 MILLION.QTRLY LOSS PER SHARE $1.15.Q3 EARNINGS PER SHARE VIEW $-1.20 -- THOMSON REUTERS I/B/E/S.

Flexion Therapeutics Reports Q2 Loss Per Share Of $1.16

Aug 7 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS SECOND-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 SALES $3.8 MILLION VERSUS I/B/E/S VIEW $4.3 MILLION.QTRLY LOSS PER SHARE $1.16.QTRLY REVENUE $3.8 MILLION.Q2 EARNINGS PER SHARE VIEW $-1.23, REVENUE VIEW $4.3 MILLION -- THOMSON REUTERS I/B/E/S.

Flexion Therapeutics Q1 Loss Per Share $1.10

May 8 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS FIRST-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.FLEXION THERAPEUTICS INC QTRLY LOSS PER SHARE $1.10.

Flexion Therapeutics Reports Q4 Sales $355,000

March 8 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 SALES $355,000.Q4 REVENUE VIEW $600,000 -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $-1.11, REVENUE VIEW $599670.00 -- THOMSON REUTERS I/B/E/S.

Flexion Therapeutics Acquires Rights To Genequine Biotherapeutics' Non-Opioid Drug

Dec 13 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES ACQUISITION OF NOVEL, NON-OPIOID ASSET FOR OSTEOARTHRITIS OF THE KNEE.FLEXION THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT WITH GENEQUINE BIOTHERAPEUTICS GMBH TO ACQUIRE GLOBAL RIGHTS TO GQ-20.FLEXION THERAPEUTICS - CO OBTAINED EXCLUSIVE LICENSE TO UNDERLYING INTELLECTUAL PROPERTY RIGHTS FOR HUMAN USE OF GQ-203 FROM BAYLOR COLLEGE OF MEDICINE.FLEXION THERAPEUTICS - CO TO MAKE UPFRONT PAYMENT OF $2 MILLION TO GENEQUINE & MAY INCUR MILESTONE PAYMENTS OF UP TO $8.7 MILLION THROUGH PHASE 2 POC.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up